Ophthalmics - Global Partnering Report (2012-2018): Updated Deal Trends, Players and Financials - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 19, 2018--The “Global Ophthalmics Partnering 2012-2018: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.
Global Ophthalmics Partnering 2012 to 2018 provides the full collection of Ophthalmics disease deals signed between the world’s pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Ophthalmics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Ophthalmics deals.
The report presents financial deal terms values for Ophthalmics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Global Ophthalmics Partnering 2012 to 2018 includes:Trends in Ophthalmics dealmaking in the biopharma industry since 2012 Analysis of Ophthalmics deal structure Access to headline, upfront, milestone and royalty data Access to hundreds of Ophthalmics deal contract documents Comprehensive access to over 3500 Ophthalmics deal records The leading Ophthalmics deals by value since 2012 Most active Ophthalmics dealmakers since 2012
The report includes deals for the following indications: Age-related macular degeneration, Blindness, Cataracts, Conjunctivitis, Diabetic macular edema, Dry eye, Glaucoma, Ocular hypertension, Retinal detachment Retinopathy, Diabetic Retinopathy, Uveitis, plus other ophthalmic indications.
In Global Ophthalmics Partnering 2012 to 2018, available deals and contracts are listed by:Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication
Key Topics Covered
Chapter 1 - Introduction
Chapter 2 - Trends in Ophthalmics dealmaking
2.2. Ophthalmics partnering over the years
2.3. Ophthalmics partnering by deal type
2.4. Ophthalmics partnering by industry sector
2.5. Ophthalmics partnering by stage of development
2.6. Ophthalmics partnering by technology type
2.7. Ophthalmics partnering by therapeutic indication
Chapter 3 - Financial deal terms for Ophthalmics partnering
3.2. Disclosed financials terms for Ophthalmics partnering
3.3. Ophthalmics partnering headline values
3.4. Ophthalmics deal upfront payments
3.5. Ophthalmics deal milestone payments
3.6. Ophthalmics royalty rates
Chapter 4 - Leading Ophthalmics deals and dealmakers
4.2. Most active in Ophthalmics partnering
4.3. List of most active dealmakers in Ophthalmics
4.4. Top Ophthalmics deals by value
Chapter 5 - Ophthalmics contract document directory
5.2. Ophthalmics partnering deals where contract document available
Chapter 6 - Ophthalmics dealmaking by therapeutic target
6.2. Deals by Ophthalmics therapeutic target
For more information about this report visit https://www.researchandmarkets.com/research/khl2bm/global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005296/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Optical ,Optical Disorders Drugs
INDUSTRY KEYWORD: HEALTH OPTICAL PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/19/2018 05:40 AM/DISC: 12/19/2018 05:40 AM